the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Stakeholder Opinions: Female Sexual Dysfunction - Results from Datamonitor's 2005 physician survey

Published by Datamonitor Contact us : +1-860-674-8796
Published 2007/06 Content info  
Product code DC52490
Price From  US $ 3800 Order/Price list
US $ 3800 PDF by E-mail (Single User License)
US $ 9500 PDF by E-mail (Global License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Abstract

Overview

Introduction

Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system.

Scope

  • Review of the disease definition, classification and key patient segmentation for FSD
  • Assessment of the current unmet needs in the treatment of FSD
  • Exploration of the screening, presentation and referral patterns within the FSD population in the 5EU and US
  • Analysis of the prescription and treatment trends among important subcategories of FSD, such as hypoactive sexual desire disorder (HSDD)

Report Highlights

Testosterone therapies are already widely used among women with HSDD and FSAD. There is a significant market for a formally approved testosterone product for women, with 85% of prescribers willing to switch existing testosterone users onto an approved product.

There is a distinct need for more specialized services in support of those with sexual functioning problems. There is no clear referral pathway for primary care physicians and no specialist service for patients to present directly to. This causes a barrier to presentation, diagnosis and treatment.

The identification and classification of FSD is biased by physician' s perception. A woman presenting with sexual difficulties could receive a variety of diagnoses or even no diagnosis at all. There is a need not only for a more holistic approach to sexual dysfunction, but also for validated and consistent tools to assess and diagnose patients.

Reasons to Purchase

  • Understand key opinion leaders views on topical issues in the FSD market
  • View quantified, pictorial treatment pathways of FSD patients in the UK, US and Spain
  • Examine treatment trends for FSD subtypes, HSDD and female sexual arousal disorder (FSAD)
Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.